NCT01486823 - Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Healthy

Interventions

DRUG

MLDL1278A

Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.

DRUG

MLDL1278A

Single subcutaneous dose of 360 mg MLDL1278A.

Trial Locations (1)

Quintiles Drug Research Unit at Guy's Hospital, London